INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26501, 0, 'Sufentanil', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26502, 1656, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26503, 10463, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26504, 20575, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26505, 20576, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26506, 20664, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26507, 26982, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26508, 30886, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26509, 1656, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26510, 10463, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26511, 20575, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26512, 20576, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26513, 20664, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26514, 26982, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26515, 30886, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26516, 1656, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26517, 10463, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26518, 20575, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26519, 20576, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26520, 20664, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26521, 26982, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26522, 30886, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26523, 1656, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26524, 10463, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26525, 20575, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26526, 20576, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26527, 20664, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26528, 26982, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26529, 30886, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26530, 1656, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26531, 10463, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26532, 20575, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26533, 20576, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26534, 20664, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26535, 26982, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26536, 30886, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26537, 1656, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26538, 10463, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26539, 20575, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26540, 20576, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26541, 20664, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26542, 26982, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26543, 30886, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26544, 1656, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26545, 10463, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26546, 20575, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26547, 20576, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26548, 20664, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26549, 26982, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26550, 30886, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26551, 1656, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26552, 10463, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26553, 20575, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26554, 20576, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26555, 20664, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26556, 26982, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26557, 30886, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26558, 1656, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26559, 10463, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26560, 20575, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26561, 20576, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26562, 20664, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26563, 26982, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26564, 30886, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26565, 15778, 'Sulfinpyrazone', 'Hematologic Diseases', 'The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias.  Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use.  Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia.  Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.', '3', '"Multum Information Services, Inc. Expert Review Panel"|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26566, 15779, 'Sulfinpyrazone', 'Hematologic Diseases', 'The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias.  Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use.  Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia.  Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.', '3', '"Multum Information Services, Inc. Expert Review Panel"|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26567, 15778, 'Sulfinpyrazone', 'Gastrointestinal Diseases', 'The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration.  Sulfinpyrazone may commonly cause upper gastrointestinal irritation.  It may also aggravate or reactivate peptic ulcer.  Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer.  Taking the medication with food, milk, or antacids may lessen GI adverse effects.', '3', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26568, 15779, 'Sulfinpyrazone', 'Gastrointestinal Diseases', 'The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration.  Sulfinpyrazone may commonly cause upper gastrointestinal irritation.  It may also aggravate or reactivate peptic ulcer.  Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer.  Taking the medication with food, milk, or antacids may lessen GI adverse effects.', '3', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26569, 15778, 'Sulfinpyrazone', 'Dehydration', 'Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26570, 15779, 'Sulfinpyrazone', 'Dehydration', 'Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26571, 15778, 'Sulfinpyrazone', 'Kidney Diseases', 'Renal failure has occasionally been reported with the use of sulfinpyrazone.  Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment.  Adequate hydration and periodic monitoring of renal function are recommended.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26572, 15779, 'Sulfinpyrazone', 'Kidney Diseases', 'Renal failure has occasionally been reported with the use of sulfinpyrazone.  Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment.  Adequate hydration and periodic monitoring of renal function are recommended.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26573, 0, 'Sulfasalazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26574, 0, 'Sulfasalazine', 'Intestinal Obstruction', 'The use of sulfasalazine is contraindicated in patients with intestinal obstruction.  Approximately one-third of orally administered sulfasalazine is systemically absorbed from the small intestine, while the majority is metabolized by intestinal bacteria to 5-aminosalicylic acid (5-ASA) that remains in the colonic lumen and gets excreted in the feces.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26575, 0, 'Sulfasalazine', 'Urethral Obstruction', 'The use of sulfasalazine tablets is contraindicated in patients with urinary obstruction.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26576, 0, 'Sulfasalazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26577, 0, 'Sulfasalazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26578, 0, 'Sulfasalazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26579, 0, 'Sulfasalazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26580, 0, 'Sulfasalazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26581, 0, 'Sulfasalazine', 'Folic Acid Deficiency', 'Sulfasalazine may interfere with the absorption of dietary folic acid.  Folate deficiency and megaloblastic anemia have been reported.  Therapy with sulfasalazine should be administered cautiously in patients with preexisting folate deficiency or anemia secondary to folate deficiency.  Folic acid supplementation (1 mg/day) is recommended in all patients during prolonged therapy.', '2', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Halsted CH, Gandhi G, Tamura T "Sulfasalazine inhibits the absorption of folates in ulcerative colitis." N Engl J Med 305 (1981):  1513-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26582, 0, 'Sulfasalazine', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfasalazine may cause hemolytic anemia in patients with glucose-6 phosphate dehydrogenase deficiency.  This reaction is frequently dose related.  It is recommended to observe these patients closely for signs of hemolytic anemia, and if toxic reactions occur, the drug should be discontinued immediately.', '2', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26583, 0, 'Sulfasalazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26584, 15480, 'Sugammadex', 'Hemorrhage', 'Sugammadex increases the risk of coagulopathies and bleeding.  It is recommended to carefully monitor coagulation parameters in patients with known coagulopathies being treated with therapeutic anticoagulation, receiving thromboprophylaxis drugs, other than heparin and low molecular weight heparin.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26585, 15480, 'Sugammadex', 'Liver Diseases', 'Sugammadex is not metabolized nor excreted by the liver.  It is recommended to use caution when administering sugammadex to patients with hepatic impairment as no dedicated trials have been conducted in these patients.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26586, 15480, 'Sugammadex', 'Kidney Diseases', 'Sugammadex is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be higher in patients with impaired renal function.  Dosage adjustment is not required in patients with mild to moderate renal impairment.  Sugammadex is not recommended for use in patients with severe renal impairment, including those requiring dialysis, due to insufficient safety information combined with the prolonged and increased overall exposure in these patients.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26587, 5365, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26588, 10957, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26589, 27598, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26590, 5365, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26591, 10957, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26592, 27598, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26593, 0, 'Suprofen (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26594, 0, 'Suprofen (ophthalmic)', 'Blood Platelet Disorders', 'Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals.  These effects may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.', '2', 'Katz ME, Wang P "Fenoprofen-associated thrombocytopenia." Ann Intern Med 92 (1980):  262|Camba L, Joyner MV "Acute thrombocytopenia following ingestion of indomethacin." Acta Haematol 71 (1984):  350-2|Gandini R, Cunietti E, Pappalepore V, et al. "Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man." J Int Med Res 11 (1983):  243|Poldre PA "Naproxen thrombocytopenia." Am J Hematol 31 (1989):  74|Stambaugh JE Jr, Gordon RL, Geller R "Leukopenia and thrombocytopenia secondary to clinoril therapy." Lancet 2 (1980):  594|Sanz MA, Martinez JA, Gomis F, Garcia-Borras JJ "Sulindac-induced bone marrow toxicity." Lancet 2 (1980):  802-3|Rosenbaum JT, O''Connor M "Thrombocytopenia associated with sulindac." Arthritis Rheum 24 (1981):  753-4|Shojania AM, Rusen SD "Thrombocytopenia secondary to sulindac therapy." Can Med Assoc J 125 (1981):  1313|Karachalios GN, Parigorakis JG "Thrombocytopenia and sulindac." Ann Intern Med 104 (1986):  128|Buchanan GR, Martin V, Levine PH, et al. "The effects of "anti-platelet" drugs on bleeding time and platelet aggregation in normal human subjects." Am J Clin Pathol 68 (1977):  355-9|Bobrove AM "Diflunisal-associated thrombocytopenia in a patient with rheumatoid arthritis ." Arthritis Rheum 31 (1988):  148-9|Green D, Holmes GI, et al. "Effects of diflunisal on platelet function and fecal blood loss." Pharmacotherapy 3 (1983):  s65-9|Khazan U, Toth M, Mutgi A "Diclofenac sodium and bruising ." Ann Intern Med 112 (1990):  472-3|Bondeson J, Berglund S "Diclofenac-induced thrombocytopenic purpura with renal and hepatic involvement." J Intern Med 230 (1991):  543-7|Price AJ, Obeid D "Spontaneous non-gastrointestinal bleeding associated with diclofenac ." Lancet 2 (1989):  1520|Epstein M, Vickars L, Stein H "Diclofenac induced immune thrombocytopenia." J Rheumatol 17 (1990):  1403-4|Kramer MR, Levene C, Hershko C "Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy." Scand J Haematol 36 (1986):  118-20|Concannon MJ, Meng L, Welsh CF, Puckett CL "Inhibition of perioperative platelet aggregation using toradol (ketorolac)." Ann Plast Surg 30 (1993):  264-6|Bjornstad H, Vik O "Thrombocytopenic purpura associated with piroxicam." Br J Clin Pract 40 (1986):  42|"Product Information. Acular (ketorolac)." Allergan Inc  (2001):|"Product Information. Voltaren (diclofenac)." Ciba Vision Ophthalmics  (2001):|"Product Information. Ocufen (flurbiprofen ophthalmic)." Allergan Inc  (2022):|"Product Information. Profenal (suprofen ophthalmic)." Alcon Laboratories Inc  (2022):|Kim HL, Kovacs MJ "Diclofenac-associated thrombocytopenia and neutropenia." Ann Pharmacother 29 (1995):  713-5|Schafer AI "Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis." J Clin Pharmacol 35 (1995):  209-19|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|Thwaites BK, Nigus DB, Bouska GW, Mongan PD, Ayala EF, Merrill GA "Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia." Anesth Analg 82 (1996):  1176-81|Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26595, 0, 'Belimumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26596, 0, 'Belimumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc  (2004):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26597, 0, 'Belimumab', 'Depressive Disorder', 'Psychiatric events have been reported with the use of belimumab.  Caution is recommended when prescribing this agent to patients with serious depression or suicidal behavior, history of depression, or other serious psychiatric disorders.  Patients receiving belimumab should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes while on belimumab.', '2', '"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26598, 33745, 'Talazoparib', 'Hepatic Insufficiency', 'Talazoparib has not been studied in patients with moderate hepatic impairment (total bilirubin >1.5 to 3.0  upper limit of normal [ULN] and any aspartate aminotransferase [AST]) or severe hepatic impairment (total bilirubin >3.0  ULN and any AST).  No dose adjustment is required for patients with mild hepatic impairment (total bilirubin =1  ULN and AST > ULN, or total bilirubin >1.0 to 1.5  ULN and any AST).', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26599, 33745, 'Talazoparib', 'Bone Marrow Failure Disorders', 'Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia, have been reported in patients treated with talazoparib.  Therapy with talazoparib should not be started in myelosuppressed patients and patients that have not adequately recovered from hematological toxicity caused by previous therapies.  If myelosuppression occurs during therapy, dose modifications are recommended.  Patients should be closely monitored.', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26600, 33745, 'Talazoparib', 'Kidney Diseases', 'Talazoparib has not been studied in patients with severe renal impairment (CrCl < 30 mL/min) or patients requiring hemodialysis.  Caution is advised if used in these patients.  A dose reduction is recommended in patients with moderate renal impairment (CrCl 30 - 59 mL/min), and no dose adjustment is required for patients with mild renal impairment (CrCl 60 - 89 mL/min).', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26601, 0, 'Tafamidis', 'Hypothyroidism', 'Tafamidis binds to transthyretin (TTR) at the thyroxine binding sites.  The use of tafamidis may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH).  The reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin due to the high binding affinity of tafamidis to the TTR thyroxine receptor.  No corresponding clinical findings consistent with hypothyroidism have been observed.  Exercise care when using this agent in patients with hypothyroidism.', '2', '"Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26602, 0, 'Tafamidis', 'Liver Diseases', 'The use of tafamidis in patients with moderate hepatic impairment (Child-Pugh Score of 7 to 9) demonstrated decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) when compared to healthy subjects.  No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6).  Use caution when using this agent in patients with severe hepatic impairment as its effect is unknown.', '2', '"Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26603, 6116, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26604, 26395, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26605, 26396, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26606, 6116, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26607, 26395, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26608, 26396, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26609, 6116, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26610, 26395, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26611, 26396, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26612, 6116, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26613, 26395, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26614, 26396, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26615, 6116, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26616, 26395, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26617, 26396, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26618, 6116, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26619, 26395, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26620, 26396, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26621, 6116, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26622, 26395, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26623, 26396, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26624, 6116, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26625, 26395, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26626, 26396, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26627, 6116, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26628, 26395, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26629, 26396, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26630, 6116, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26631, 26395, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26632, 26396, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26633, 6116, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26634, 26395, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26635, 26396, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26636, 6116, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26637, 26395, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26638, 26396, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26639, 6116, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26640, 26395, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26641, 26396, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26642, 0, 'Tafenoquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Tafenoquine is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or unknown G6PD status due to the risk of hemolytic anemia.  All patients must be tested for G6PD deficiency prior to prescribing tafenoquine.', '3', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26643, 0, 'Tafenoquine', 'Psychotic Disorders', 'Tafenoquine is contraindicated in patients with a history of psychotic disorders or current psychotic symptoms such as hallucinations, delusions, and/or grossly disorganized behavior.  If psychotic symptoms occur (hallucinations, delusions), consider discontinuation of tafenoquine and a prompt evaluation by a mental health professional as soon as possible.  Other psychiatric symptoms, such as changes in mood, anxiety, insomnia, and nightmares, should be promptly evaluated by a medical professional if they are moderate and last more than three days or are severe.', '3', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26644, 0, 'Tafenoquine', 'Hepatic Insufficiency', 'The pharmacokinetics of tafenoquine have not been studied in patients with renal or hepatic impairment.  If tafenoquine is administered to such patients, close monitoring for adverse reactions is needed.', '2', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26645, 0, 'Tacrine', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Baldessarini RJ, Gelenberg AJ "Using physostigmine safely." Am J Psychiatry 136 (1979):  1608-9|Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry 142 (1985):  738-40|Dysken MW, Janowsky DS "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry 46 (1985):  446-7|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26646, 0, 'Tacrine', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26647, 0, 'Tacrine', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26648, 0, 'Tacrine', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|el-Yousef MK, Janowsky D, Davis JM, Sekerke HJ "Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study." Am J Psychiatry 130 (1973):  141-5|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26649, 0, 'Tacrine', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26650, 0, 'Tacrine', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26651, 0, 'Tacrine', 'Liver Diseases', 'The use of tacrine is contraindicated in patients with a history of tacrine-induced jaundice confirmed by elevated total bilirubin greater than 3.0 mg/dl.  Elevations in liver function tests (LFTs) have been reported in as many as 50% of patients receiving tacrine. Twenty-five percent of patients may experience a 3 fold rise in ALT and 7% a 10 fold rise in ALT.  LFTs should be monitored prior to initiation of tacrine therapy is initiated and when dosages are altered.  Tacrine undergoes extensive first-pass metabolism by the liver (CYP450-1A2) to multiple forms.  The metabolic and therapeutic activity of tacrine can be altered in patients with compromised hepatic function and therapy with tacrine should be administered cautiously in these patients.', '3', 'Ford JM, Truman CA, Wilcock GK, Roberts CJ "Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer''s disease." Clin Pharmacol Ther 53 (1993):  691-5|Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A "Long-term hepatotoxicity of tacrine." Lancet 1 (1989):  729|Ames DJ, Bhathal PS, Davies BM, Fraser JR "Hepatotoxicity of tetrahydroaminoacridine." Lancet 1 (1988):  887|Ames DJ, Bhathal PS, Davies BM, Fraser JR, Gibson PR, Roberts S "Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine." Aust N Z J Med 20 (1990):  193-5|Hammel P, Larrey D, Bernuau J, Kalafat M, Freneaux E, Babany G, Degott C, Feldmann G, Pessayre D, Benhamou JP "Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer''s disease." J Clin Gastroenterol 12 (1990):  329-31|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Knapp MJ, Knopman DS, Solomon PR, et al. "A 30-week randomized controlled trial of high-dose tacrine in patients with alzheimers disease." JAMA 271 (1994):  985-91|Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW "Hepatotoxic effects of tacrine administration in patients with alzheimers disease." JAMA 271 (1994):  992-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26652, 0, 'Tacrine', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26653, 0, 'Talimogene laherparepvec', 'IMMUNE SUPPRESSION', 'Talimogene laherparepvec is a live, attenuated herpes simplex virus.  The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.', '3', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26654, 0, 'Talimogene laherparepvec', 'Immune Deficiency Disease', 'Do not administer talimogene laherparepvec to patients with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.', '3', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26655, 0, 'Talimogene laherparepvec', 'Autoimmune Diseases', 'The use of talimogene laherparepvec may result in immune-mediated events.  Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events.  Close monitoring is recommended.', '2', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26656, 0, 'Talimogene laherparepvec', 'Multiple Myeloma', 'Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma.  It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment.  Close monitoring is recommended.', '2', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26657, 0, 'Tasimelteon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26658, 0, 'Tasimelteon', 'Kidney Failure, Chronic', 'Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26659, 0, 'Tasimelteon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26660, 0, 'Tasimelteon', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26661, 12786, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26662, 13379, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26663, 24467, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26664, 24468, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26665, 26432, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26666, 27949, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26667, 27951, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26668, 28331, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26669, 29843, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26670, 29844, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26671, 12786, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26672, 13379, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26673, 24467, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26674, 24468, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26675, 26432, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26676, 27949, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26677, 27951, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26678, 28331, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26679, 29843, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26680, 29844, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26681, 3184, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26682, 6831, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26683, 9228, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26684, 9229, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26685, 11160, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26686, 11161, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26687, 11162, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26688, 15376, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26689, 16953, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26690, 21318, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26691, 22063, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26692, 22204, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26693, 27871, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26694, 27890, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26695, 31881, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26696, 32696, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26697, 3184, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26698, 6831, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26699, 9228, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26700, 9229, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26701, 11160, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26702, 11161, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26703, 11162, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26704, 15376, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26705, 16953, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26706, 21318, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26707, 22063, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26708, 22204, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26709, 27871, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26710, 27890, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26711, 31881, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26712, 32696, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26713, 3184, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26714, 6831, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26715, 9228, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26716, 9229, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26717, 11160, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26718, 11161, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26719, 11162, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26720, 15376, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26721, 16953, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26722, 21318, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26723, 22063, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26724, 22204, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26725, 27871, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26726, 27890, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26727, 31881, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26728, 32696, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26729, 3184, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26730, 6831, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26731, 9228, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26732, 9229, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26733, 11160, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26734, 11161, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26735, 11162, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26736, 15376, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26737, 16953, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26738, 21318, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26739, 22063, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26740, 22204, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26741, 27871, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26742, 27890, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26743, 31881, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26744, 32696, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26745, 11196, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26746, 13242, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26747, 13502, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26748, 13503, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26749, 13504, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26750, 13514, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26751, 13515, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26752, 13516, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26753, 13517, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26754, 13518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26755, 13519, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26756, 13520, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26757, 13521, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26758, 25434, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26759, 28422, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26760, 29518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26761, 11196, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26762, 13242, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26763, 13502, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26764, 13503, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26765, 13504, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26766, 13514, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26767, 13515, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26768, 13516, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26769, 13517, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26770, 13518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26771, 13519, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26772, 13520, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26773, 13521, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26774, 25434, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26775, 28422, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26776, 29518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26777, 11196, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26778, 13242, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26779, 13502, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26780, 13503, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26781, 13504, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26782, 13514, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26783, 13515, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26784, 13516, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26785, 13517, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26786, 13518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26787, 13519, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26788, 13520, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26789, 13521, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26790, 25434, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26791, 28422, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26792, 29518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26793, 11196, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26794, 13242, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26795, 13502, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26796, 13503, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26797, 13504, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26798, 13514, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26799, 13515, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26800, 13516, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26801, 13517, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26802, 13518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26803, 13519, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26804, 13520, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26805, 13521, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26806, 25434, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26807, 28422, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26808, 29518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26809, 11196, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26810, 13242, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26811, 13502, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26812, 13503, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26813, 13504, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26814, 13514, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26815, 13515, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26816, 13516, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26817, 13517, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26818, 13518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26819, 13519, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26820, 13520, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26821, 13521, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26822, 25434, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26823, 28422, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26824, 29518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26825, 11196, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26826, 13242, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26827, 13502, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26828, 13503, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26829, 13504, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26830, 13514, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26831, 13515, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26832, 13516, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26833, 13517, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26834, 13518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26835, 13519, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26836, 13520, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26837, 13521, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26838, 25434, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26839, 28422, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26840, 29518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26841, 11196, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26842, 13242, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26843, 13502, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26844, 13503, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26845, 13504, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26846, 13514, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26847, 13515, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26848, 13516, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26849, 13517, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26850, 13518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26851, 13519, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26852, 13520, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26853, 13521, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26854, 25434, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26855, 28422, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26856, 29518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26857, 6400, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26858, 16897, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26859, 20727, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26860, 27647, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26861, 27648, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26862, 27649, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26863, 6400, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26864, 16897, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26865, 20727, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26866, 27647, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26867, 27648, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26868, 27649, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26869, 6400, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26870, 16897, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26871, 20727, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26872, 27647, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26873, 27648, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26874, 27649, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26875, 6400, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26876, 16897, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26877, 20727, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26878, 27647, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26879, 27648, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26880, 27649, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26881, 8949, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26882, 11153, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26883, 11155, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26884, 27883, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26885, 27884, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26886, 27885, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26887, 8949, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26888, 11153, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26889, 11155, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26890, 27883, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26891, 27884, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26892, 27885, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26893, 8949, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26894, 11153, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26895, 11155, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26896, 27883, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26897, 27884, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26898, 27885, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26899, 8949, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26900, 11153, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26901, 11155, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26902, 27883, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26903, 27884, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26904, 27885, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26905, 8949, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26906, 11153, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26907, 11155, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26908, 27883, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26909, 27884, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26910, 27885, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26911, 4949, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26912, 27741, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26913, 27742, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26914, 27743, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26915, 4949, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26916, 27741, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26917, 27742, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26918, 27743, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26919, 4949, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26920, 27741, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26921, 27742, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26922, 27743, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26923, 4949, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26924, 27741, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26925, 27742, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26926, 27743, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26927, 4949, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26928, 27741, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26929, 27742, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26930, 27743, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26931, 4949, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26932, 27741, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26933, 27742, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26934, 27743, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26935, 4949, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26936, 27741, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26937, 27742, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26938, 27743, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26939, 4949, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26940, 27741, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26941, 27742, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26942, 27743, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26943, 4949, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26944, 27741, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26945, 27742, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26946, 27743, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26947, 4949, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26948, 27741, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26949, 27742, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26950, 27743, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26951, 4949, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26952, 27741, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26953, 27742, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26954, 27743, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26955, 4949, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26956, 27741, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26957, 27742, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26958, 27743, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26959, 4949, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26960, 27741, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26961, 27742, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26962, 27743, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26963, 0, 'Suvorexant', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26964, 0, 'Suvorexant', 'Kidney Failure, Chronic', 'Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26965, 0, 'Suvorexant', 'Lung Diseases', 'Suvorexant has respiratory depressant effects and should be used with caution in patients with compromised respiratory function.  Suvorexant has not been studied in patients with severe sleep apnea and severe COPD and should not be used in these patients.', '3', '"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26966, 0, 'Suvorexant', 'Narcolepsy', 'The use of suvorexant is contraindicated in patient with narcolepsy.', '3', '"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26967, 0, 'Suvorexant', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26968, 0, 'Suvorexant', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26969, 16929, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26970, 27970, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26971, 30009, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26972, 16929, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26973, 27970, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26974, 30009, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26975, 3617, 'Belladonna', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26976, 3617, 'Belladonna', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Blamoutier J "Comparative trial of two antihistamines, mequitazine and brompheniramine." Curr Med Res Opin 5 (1978):  366-70|"Azatadine (optimine)--a new antihistamine." Med Lett Drugs Ther 19 (1977):  77-9|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26977, 3617, 'Belladonna', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|O''Connor PS, Mumma JV "Atropine toxicity." Am J Ophthalmol 99 (1985):  613-4|Clearkin LG "Angle closure glaucoma precipitated by atropine." Arch Intern Med 152 (1992):  880|Berdy GJ, Berdy SS, Odin LS, Hirst LW "Angle closure glaucoma precipitated by aerosolized atropine." Arch Intern Med 151 (1991):  1658-60|Pecora JL "Malignant glaucoma worsened by miotics in a postoperative angle- closure glaucoma patient." Ann Ophthalmol 11 (1979):  1412-4|Holland MG "Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs." Ann Ophthalmol 6 (1974):  661-4|Kanto J "New aspects in the use of atropine." Int J Clin Pharmacol Ther Toxicol 21 (1983):  92-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26978, 3617, 'Belladonna', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|O''Kelly SW, Spargo PM "Postoperative urinary retention in men." BMJ 302 (1991):  1403-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26979, 3617, 'Belladonna', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', 'Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26980, 3617, 'Belladonna', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26981, 3617, 'Belladonna', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'Brown JW "Toxic megacolon associated with loperamide therapy." JAMA 241 (1979):  501-2|Walley T, Milson D "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J 66 (1990):  582|"Product Information. Imodium (loperamide)." Janssen Pharmaceuticals  (2001):|Marshall WF Jr, Rosenthal P, Merritt RJ "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr 9 (1989):  532-4|"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26982, 3617, 'Belladonna', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|Lowenthal DT, Reidenberg MM "The heart rate response to atropine in uremic patients, obese subjects before and during fasting, and patients with other chronic illnesses." Proc Soc Exp Biol Med 139 (1972):  390-3|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Cooper MJ, Abinader EG "Atropine-induced ventricular fibrillation: case report and review of the literature." Am Heart J 97 (1979):  225-8|Das G, Talmers FN, Weissler AM "New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man." Am J Cardiol 36 (1975):  281-5|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Bradshaw EG "Dysrhythmias associated with oral surgery." Anaesthesia 31 (1976):  13-7|Horgan J "Atropine and ventricular tachyarrhythmia." JAMA 223 (1973):  693|Zsigmond EK, Matsuki A, Sharafabadi C "Atropine and cardiac arrhythmia." N Engl J Med 288 (1973):  635|Massumi RA, Mason DT, Amsterdam EA, DeMaria A, Miller RR, Scheinman MM, Zelis R "Ventricular fibrillation and tachycardia after intravenous atropine for treatment of bradycardias." N Engl J Med 287 (1972):  336-8|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|Lazzari JO, Benchuga EG, Elizari MV, Rosenbaum MB "Ventricular fibrillation after intravenous atropine in a patient with atrioventricular block." Pacing Clin Electrophysiol 5 (1982):  196-200|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26983, 3617, 'Belladonna', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '"Product Information. Antivert (meclizine)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26984, 3617, 'Belladonna', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Richman S "Adverse effect of atropine during myocardial infarction. Enchancement of ischemia following intravenously administered atropine." JAMA 228 (1974):  1414-6|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26985, 3617, 'Belladonna', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26986, 3617, 'Belladonna', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Dow TG, Brock-Utne JG, Rubin J, Welman S, Dimopoulos GE, Moshal MG "The effect of atropine on the lower esophageal sphincter in late pregnancy." Obstet Gynecol 51 (1978):  426-30|Howells TH "The administration of metoclopramide with atropine." Anaesthesia 32 (1977):  677|Brock-Utne JG, Rubin J, Downing JW, Dimopoulos GE, Moshal MG, Naicker M "The administration of metoclopramide with atropine. A drug interaction effect on the gastro-oesophageal sphincter in man." Anaesthesia 31 (1976):  1186-90|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26987, 3617, 'Belladonna', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', 'Famewo CE "A re-evaluation of anticholergic premedication." Can Anaesth Soc J 24 (1977):  39-41|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26988, 3617, 'Belladonna', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26989, 3617, 'Belladonna', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26990, 3617, 'Belladonna', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Atropisol (atropine ophthalmic)." Ciba Vision Ophthalmics  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26991, 3617, 'Belladonna', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26992, 3617, 'Belladonna', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', '"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26993, 3617, 'Belladonna', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983):  957-9|Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973):  348-50|Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986):  571|Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978):  243-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26994, 0, 'Teduglutide', 'Pancreatic Diseases', 'Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide.  For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed.  If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26995, 0, 'Teduglutide', 'Heart Failure', 'Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide.  This was probably related to enhanced fluid absorption associated with the medication.  If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease.  If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26996, 0, 'Teduglutide', 'Intestinal Obstruction', 'Intestinal obstruction has been reported in clinical trials with teduglutide.  In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed.  Treatment may be restarted when the obstructive episode resolves, if clinically indicated.  Caution is advised in patients with risk factors for intestinal obstruction.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26997, 0, 'Teduglutide', 'Liver Failure', 'Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment.  Caution and monitoring is advised.  Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide.  However, no dose adjustment is necessary for patients with mild and moderate liver impairment.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26998, 0, 'Teduglutide', 'Neoplasms', 'Based on the pharmacologic activity and findings in animals, teduglutide has the potential to cause hyperplastic changes including neoplasia.  In patients at increased risk for malignancy, the clinical decision to use teduglutide should be considered only if the benefits outweigh the risks.  In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), therapy should be discontinued.  Patients with colorectal polyps, should have these removed within 6 months prior to starting treatment with teduglutide.  In patients with active non- gastrointestinal malignancy, the clinical decision to continue therapy should be made based on risk- benefit considerations.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26999, 0, 'Teduglutide', 'Kidney Diseases', 'Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment.  The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27000, 27986, 'Tegaserod', 'Intestinal Obstruction', 'The use of tegaserod is contraindicated in patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.  Stimulation of gastrointestinal motility might be harmful in these conditions.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
